The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10491 malaria professionals are enjoying the free benefits of MalariaWorld today

Primaquine

COVID-19: Possible Cause of Induction of Relapse of Plasmodium vivax Infection

July 7, 2020 - 13:11 -- Open Access
Author(s): 
Kishore R, Dhakad S, Arif N, Dar L, Mirdha BR, Aggarwal R, Kabra SK
Reference: 
Indian J Pediatr. 2020 Jul 3:1-2

To the Editor: In ongoing pandemic of novel corona virus disease (COVID-19), clinicians are observing atypical manifestations of the disease.

NOT Open Access | Prevalence of Glucose 6-Phosphate Dehydrogenase Variants in Malaria-Endemic Areas of South Central Timor, Eastern Indonesia

July 1, 2020 - 16:33 -- NOT Open Access
Author(s): 
Sulistyaningrum N, Arlinda D, Chaijaroenkul W, et al.
Reference: 
Am J Trop Med Hyg. 2020 Jun 29

Primaquine is an effective anti-hypnozoite drug for Plasmodium vivax and Plasmodium ovale. However, it can trigger erythrocyte hemolysis in people with glucose 6-phosphate dehydrogenase (G6PD) deficiency. In a previous report from South Central Timor (SCT), Indonesia, we described the prevalence of Vanua Lava, Chatham, and Viangchan variants; in this study, other G6PD variants (Kaiping, Coimbra, Gaohe, Canton, and Mahidol) were subsequently analyzed. For clarity, all of these results are described together.

Parasite clearance, cure rate, post-treatment prophylaxis and safety of standard 3-day versus an extended 6-day treatment of artemether–lumefantrine and a single low-dose primaquine for uncomplicated Plasmodium falciparum malaria in Bagamoyo district, Tan

June 26, 2020 - 15:41 -- Open Access
Author(s): 
Lwidiko E. Mhamilawa, Billy Ngasala, Ulrika Morris, Eliford Ngaimisi Kitabi, Rory Barnes, Aung Paing Soe, Bruno P. Mmbando, Anders Björkman and Andreas Mårtensson
Reference: 
Malaria Journal 2020 19:216, 23 June 2020

Artemisinin-based combination therapy (ACT) resistant Plasmodium falciparum represents an increasing threat to Africa. Extended ACT regimens from standard 3 to 6 days may represent a means to prevent its development and potential spread in Africa.

Estimating the Proportion of Plasmodium vivax Recurrences Caused by Relapse: A Systematic Review and Meta-Analysis

June 15, 2020 - 15:06 -- Open Access
Author(s): 
Commons RJ, Simpson JA, Watson J, White NJ, Price RN
Reference: 
Am J Trop Med Hyg. 2020 Jun 8

Plasmodium vivax and Plasmodium ovale form dormant liver hypnozoites that can reactivate weeks to months following initial infection. Malaria recurrences caused by relapses are an important cause of morbidity and source of transmission. To estimate the proportions of P. vivax malaria recurrences caused by relapses in different geographical locations, we systematically reviewed clinical efficacy studies of uncomplicated P. vivax malaria, in which patients were randomized to treatment with or without radical cure primaquine regimens and were followed up for 1 year.

NOT Open Access | Case report: recurrence of Plasmodium vivax malaria due to defective cytochrome P450 2D6 function in Pos Lenjang, Pahang, Malaysia

June 9, 2020 - 15:32 -- NOT Open Access
Author(s): 
Mat Salleh NH, Rahman MFA, Samsusah S, De Silva JR, Ng DC, Ghozali AH, Tan JH, Lai MY, Amir A, Liew JWK, Lau YL
Reference: 
Transactions of The Royal Society of Tropical Medicine and Hygiene, traa042

Five children in Pos Lenjang, Pahang, Malaysia were PCR-positive for vivax malaria and were admitted to the hospital from 5 to 26 July 2019. One of the patients experienced three episodes of recurrence of vivax malaria. Microsatellite analysis showed that reinfection is unlikely.

Quantification of glucose-6-phosphate dehydrogenase activity by spectrophotometry: A systematic review and meta-analysis

May 19, 2020 - 14:28 -- Open Access
Author(s): 
Pfeffer DA, Ley B, Ric N. Price, et al.
Reference: 
PLoS Med 17(5): e1003084

The radical cure of Plasmodium vivax and P. ovale requires treatment with primaquine or tafenoquine to clear dormant liver stages. Either drug can induce haemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, necessitating screening. The reference diagnostic method for G6PD activity is ultraviolet (UV) spectrophotometry; however, a universal G6PD activity threshold above which these drugs can be safely administered is not yet defined. Our study aimed to quantify assay-based variation in G6PD spectrophotometry and to explore the diagnostic implications of applying a universal threshold.

NOT Open Access | Case Report: Primaquine Failure for Radical Cure of Plasmodium vivax Malaria in Gambella, Ethiopia

May 13, 2020 - 14:45 -- NOT Open Access
Author(s): 
Teklehaimanot A, Teklehaimanot H, Girmay A, Woyessa A
Reference: 
Am J Trop Med Hyg. 2020 May 11

Failures of primaquine for the treatment of relapsed Plasmodium vivax malaria is a serious challenge to malaria elimination in Ethiopia, where P. vivax accounts for up to 40% of malaria infections. We report here occurrence of a total of 15 episodes of primaquine treatment failure for radical cure in three historical P. vivax malaria patients from Gambella, Ethiopia, during 8–16 months of follow-up in 1985–1987.

Safety, Pharmacokinetics, and Mosquito-Lethal Effects of Ivermectin in Combination With Dihydroartemisinin-Piperaquine and Primaquine in Healthy Adult Thai Subjects

May 7, 2020 - 13:34 -- Open Access
Author(s): 
Kobylinski KC, Jittamala P, Tarning J, et al.
Reference: 
Clin Pharmacol Ther. 2020 May;107(5):1221-1230

Mass administration of antimalarial drugs and ivermectin are being considered as potential accelerators of malaria elimination. The safety, tolerability, pharmacokinetics, and mosquito‐lethal effects of combinations of ivermectin, dihydroartemisinin‐piperaquine, and primaquine were evaluated. Coadministration of ivermectin and dihydroartemisinin‐piperaquine resulted in increased ivermectin concentrations with corresponding increases in mosquito‐lethal effect across all subjects.

Significant efficacy of single low dose primaquine compared to stand alone artemisinin combination therapy in reducing gametocyte carriage in Cambodian patients with uncomplicated multidrug resistant Plasmodium falciparum malaria

March 19, 2020 - 09:13 -- Open Access
Author(s): 
Vantaux A, Kim S, Piv E, Chy S, Berne L, Khim N, Lek D, Siv S, Mukaka M, Taylor WR, Ménard D
Reference: 
Antimicrob Agents Chemother. 2020 Mar 16. pii: AAC.02108-19

Since 2012, single low dose of primaquine (SLDPQ, 0.25mg/kg) has been recommended with artemisinin-based combination therapies, as first-line treatment of acute uncomplicated Plasmodium falciparum malaria, to interrupt its transmission, especially in low transmission settings of multidrug, including artemisinin, resistance. Policy makers in Cambodia have been reluctant to implement this recommendation due to primaquine safety concerns and lack of data on its efficacy.

Corrigendum to: Hemolytic Dynamics of Weekly Primaquine Antirelapse Therapy Among Cambodians With Acute Plasmodium vivax Malaria With or Without Glucose-6-Phosphate Dehydrogenase Deficiency

February 22, 2020 - 17:12 -- Open Access
Author(s): 
Taylor WRJ, Kheng S, Muth S, Tor P, Kim S, Bjorge S, Topps N, Kosal K, Sothea K, Souy P, Char CM, Vanna C, Ly P, Khieu V, Christophel E, Kerleguer A, Pantaleo A, Mukaka M, Menard D, Baird JK
Reference: 
The Journal of Infectious Diseases, Volume 221, Issue 5, 1 March 2020, Page 854

In “Hemolytic Dynamics of Weekly Primaquine Antirelapse Therapy Among Cambodians With Acute Plasmodium vivax Malaria With or Without Glucose-6-Phosphate Dehydrogenase Deficiency” by Taylor et al [J Infect Dis 2019; 220(11): 1750–60], P values should be P < 0.001 where 0.000 is written. This has been updated in the article.

The authors regret these errors.

Pages

Subscribe to RSS - Primaquine